

DAFTAR PUSTAKA

- Abdelhameed, F., Kite, C., Lagojda, L., Dallaway, A., Chatha, K.K., Chaggar, S.S., Dalamaga, M., Kassi, E., Kyrou, I., Randeve, H.S., 2024. Non - invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction - associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. *Curr. Obes. Rep.* 510–531. doi:10.1007/s13679-024-00574-z
- Abenavoli, L., Milic, N., Di Renzo, L., Preveden, T., Medic-Stojanoska, M., & De Lorenzo, A. (2020). Metabolic aspects of adult patients with nonalcoholic fatty liver disease. *World Journal of Gastroenterology*, 26(24), 3237–3250. <https://doi.org/10.3748/wjg.v26.i24.3237>
- Alves-Bezerra, M., & Cohen, D. E. (2018). Triglyceride metabolism in the liver. *Comprehensive Physiology*, 8(1), 1–22. <https://doi.org/10.1002/cphy.c170012>
- Arneth, B., 2024. Mechanisms of Insulin Resistance in Patients with Obesity. *Endocrines* 5: 153–165. doi:10.3390/endocrines5020011
- Avagimyan, A., Pogosova, N., Fogacci, F., Aghajanova, E., Djndoyan, Z., Patoulas, D., et al., 2025. Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine. *Int. J. Cardiol.* 418: 132663. doi:10.1016/j.ijcard.2024.132663
- Azizi N, Naghibi H, Shakiba M, Morsali M, Zarei D, Abbastabar H, Ghanaati H. 2025. Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis. *Eur Radiol.* 35(4):1794–1807. <https://doi.org/10.1007/s00330-024-11001-1>
- Baars, T., Gieseler, R.K., Patsalis, P.C., Canbay, A., 2022. Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. *Metabolism.* 130: 155179. doi:10.1016/j.metabol.2022.155179
- Ballestri S, Mantovani A, Byrne CD, Lonardo A, Targher G. 2021. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. *Metab Target Organ Damage.* 1:7. <http://dx.doi.org/10.20517/mtod.2021.05>
- Bergman BC, Goodpaster BH. 2020. Exercise and muscle lipid content, composition, and localization: influence on muscle insulin sensitivity. *Diabetes.* 69(5):848–858. <https://doi.org/10.2337/dbi18-0042>
- Brown, M. S., & Goldstein, J. L. (2008). Selective insulin resistance in metabolic disease. *Cell Metabolism*, 7(2), 95–96. <https://doi.org/10.1016/j.cmet.2007.12.004>
- Browning JD, Horton JD. 2004. Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest.* 114(2):147–152. <https://doi.org/10.1172/JCI22422>

- Bruns, C.E., Stalder, K.J., 2019. Genetics and health, Diseases of Swine. doi:10.1002/9781119350927.ch3
- Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., et al., 2007. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*, 56(7), 1761–1772. <https://doi.org/10.2337/db06-1491>
- Cigrovski Berkovic, M., Bilic-Curcic, I., Mrzljak, A., Cigrovski, V., & Vcev, A. 2021. The role of physical activity in the management of non-alcoholic fatty liver disease. *World Journal of Gastroenterology*, 27(30), 4962–4974. <https://doi.org/10.3748/wjg.v27.i30.4962>
- Castera, L., 2019. HHS Public Access. *Physiol. Behav.* 176: 139–148. doi:10.1053/j.gastro.2018.12.036.Noninvasive
- Chalasanani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, et al., 2018. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 67: 328–357. doi:10.1002/hep.29367
- Chen Y, Ma L, Han Z, Xiong P. 2024. The global burden of disease attributable to high body mass index in 204 countries and territories: Findings from 1990 to 2019 and predictions to 2035. *Diabetes Obes Metab.* 26(9):3998–4010. <https://doi.org/10.1111/dom.15748>
- Cheung A, Ahmed A. Nonalcoholic fatty liver disease and chronic kidney disease: a review of links and risks. 2021. *Clin Exp Gastroenterol.* 14:457–465. <https://doi.org/10.2147/CEG.S226130>
- Ciardullo S, Perseghin G. 2024. From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction. *Metab Target Organ Damage.* 4:30. <http://dx.doi.org/10.20517/mtod.2024.39>
- Cusi, K. (2024). Managing insulin resistance: The forgotten pathophysiological component of type 2 diabetes. *The Lancet Diabetes & Endocrinology*, 12(9), 671–683.
- Dahlan, M.S., 2014. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Jakarta: Salemba Medika.
- Doonan, R.J., Hausvater, A., Scallan, C., Mikhailidis, D.P., Pilote, L., Daskalopoulou, S.S., 2010. The effect of smoking on arterial stiffness. *Hypertens. Res.* 33: 398–410. doi:10.1038/hr.2010.25
- Dundar, C., Terzi, O., Arslan, H.N., 2023. Comparison of the ability of HOMA-IR, VAI, and TyG indexes to predict metabolic syndrome in children with obesity: a cross-sectional study. *BMC Pediatr.* 23: 1–9. doi:10.1186/s12887-023-03892-8
- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. 2020. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol.* 73(1):202–209. <https://doi.org/10.1016/j.jhep.2020.03.039>
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). 2024. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver

- disease (MASLD): Executive Summary. *Diabetologia*. 67(11):2375–2392. doi:10.1007/s00125-024-06196-3
- Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M., Sanyal, A.J., 2018. Mechanisms of NAFLD development and therapeutic strategies, *Nature Medicine*. doi:10.1038/s41591-018-0104-9
- Gayoso-Diz, P., Otero-González, A., Rodriguez-Alvarez, M.X., Gude, F., García, F., De Francisco, et al., 2013. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional study. *BMC Endocr. Disord.* 13. doi:10.1186/1472-6823-13-47
- Godoy-Matos, A.F., Silva Júnior, W.S., Valerio, C.M., 2020. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. *Diabetol. Metab. Syndr.* 12: 1–20. doi:10.1186/s13098-020-00570-y
- Guerrero-Romero, F., Simental-Mendía, L.E., González-Ortiz, M., Martínez-Abundis, E., Ramos-Zavala, M.G., Hernández-González, S.O., et al., 2010. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. *J. Clin. Endocrinol. Metab.* 95: 3347–3351. doi:10.1210/jc.2010-0288
- Haam, J.H., Kim, B.T., Kim, E.M., Kwon, H., Kang, J.H., Park, J.H., et al., 2023. Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. *J. Obes. Metab. Syndr.* 32: 121–129. doi:10.7570/jomes23031
- Haghshomar, M., Antonacci, D., Smith, A.D., Thaker, S., Miller, F.H., Borhani, A.A., 2024. Diagnostic accuracy of CT for the detection of hepatic steatosis: a systematic review and meta-analysis. *Radiology*. 313(2):e241171. <https://doi.org/10.1148/radiol.241171>
- Hagström H, 2024a. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. *J Hepatol.* 80(2):e76–e77.
- Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. 2024b. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. *The Lancet Gastroenterology & Hepatology*, 9(10), 944–954.
- Hossain ,S., Sultana, S., Zaman KMS., Shafiq, S., Rahman, A.K.M.S., Hossain, S.M.Z., et al., 2020. Triglyceride and glucose index (TyG) is a reliable biomarker to predict non-alcoholic fatty liver disease. *J Biosci Med.*8:124–136. <https://doi.org/10.4236/jbm.2020.811012>
- Huang, J.F., Tsai, P.C., Yeh, M.L., Huang, C.F., Huang, C.I., Hsieh, M.H., et al., 2020. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. *J Formos Med Assoc.* 119(1 Pt 1):89–96. <https://doi.org/10.1016/j.jfma.2019.03.014>
- Janssen, J.A.M.J.L., 2021. Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer. *Int. J. Mol. Sci.* 22. doi:10.3390/ijms22157797
- Juanola, O., Martínez-López, S., Francés, R., Gómez-Hurtado, I., 2021. Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors. *Int. J. Environ. Res. Public Health* 18. doi:10.3390/ijerph18105227

- Karlas, T., Petroff, D., Garnov, N., Böhm, S., Tenckhoff, H., Wittekind, C., et al., 2014. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. *PLoS One* 9. doi:10.1371/journal.pone.0091987
- Karlas, T., Petroff, D., Sasso, M., Fan, J.G., Mi, Y.Q., de Lédinghen, V., et al., 2017. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. *J. Hepatol.* 66: 1022–1030. doi:10.1016/j.jhep.2016.12.022
- Khamseh, M.E., Malek, M., Abbasi, R., Taheri, H., Lahouti, M., Alaei-Shahmiri, F., 2021. Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity. *Metab. Syndr. Relat. Disord.* 19: 167–173. doi:10.1089/met.2020.0109
- Khamseh, M.E., Malek, M., Jahangiri, S., Nobarani, S., Hekmatdoost, A., Salavatizadeh, M., et al., 2024. Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis. *Dig. Dis. Sci.* 69: 1430–1443. doi:10.1007/s10620-024-08309-9
- Kim, H.S., Cho, Y.K., Kim, E.H., Lee, M.J., Jung, C.H., Park, J.Y., et al., 2022. Triglyceride glucose-waist circumference is superior to the homeostasis model assessment of insulin resistance in identifying nonalcoholic fatty liver disease in healthy subjects. *J. Clin. Med.* 11. doi:10.3390/jcm11010041
- Kim, J. H., (2022). The triglyceride-glucose index and its derivatives in predicting non-alcoholic fatty liver disease. *Journal of Clinical Medicine*, 11(12), 3412.
- Kurniawan, L.B., Info, A., 2024. Triglyceride-Glucose Index As A Biomarker Of Insulin Resistance, Diabetes Mellitus, Metabolic Syndrome, And Cardiovascular Disease: A Review. *Ejifcc* 35: 44.
- Kurniawati, F., Mudjanarko, S.W., Soelistijo, S.A., Sugihartono, T., 2024. Association of Triglyceride and Glucose Index with Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients. *Pharmacogn. J.* 16: 1077–1080. doi:10.5530/pj.2024.16.174
- Lee, T.B., Kueh, M.T.W., Jain, V., Razavi, A.C., Alebna, P., Chew, N.W.S., Mehta, A., 2023. Biomarkers of Hepatic Dysfunction and Cardiovascular Risk. *Curr. Cardiol. Rep.* 25: 1783–1795. doi:10.1007/s11886-023-01993-5
- Li, S., Feng, L., Ding, J., Zhou, W., Yuan, T., Mao, J., 2023. Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults. *BMC Gastroenterol.* 23: 1–9. doi:10.1186/s12876-023-03007-8
- Lin, Y.C., Chou, S.C., Huang, P.T., Chiou, H.Y., 2011. Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. *Ann Hepatol.* 10(2):125–132.
- Ling, Q., Chen, J., Liu, X., Xu, Y., Ma, J., Yu, P., et al., 2023. The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose–response meta-analysis. *Front. Endocrinol. (Lausanne).* 13. doi:10.3389/fendo.2022.1043169

- Liu, X.C., He, G.D., Lo, K., Huang, Y.Q., Feng, Y.Q., 2021. The triglyceride-glucose index, an insulin resistance marker, was non-linearly associated with all-cause and cardiovascular mortality in the general population. *Front Cardiovasc Med.* 7:628109. <https://doi.org/10.3389/fcvm.2020.628109>
- Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P., 2025. Nonalcoholic fatty liver disease : A precursor of the metabolic syndrome. *Dig. Liver Dis.* 47: 181–190. doi:10.1016/j.dld.2014.09.020
- Man, S., Deng, Y., Ma, Y., Yang, X., Wang, X., Fu, J., et al., 2024. Association between weight change, waist circumference change, and the risk of nonalcoholic fatty liver disease in individuals with metabolically healthy overweight or obesity and metabolically unhealthy overweight or obesity. *Obes. Res. Clin. Pract.* 18: 109–117. doi:10.1016/j.orcp.2024.02.007
- Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018). Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis. *Diabetes Care*, 41(2), 372–382.
- Machida, T., Obara, T., Miyazaki, M., Inoue, J., & Mano, N. (2022). Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. *Annals of Hepatology*, 27(3). <https://doi.org/10.1016/j.aohep.2022.100685>
- Nieman, D. C. (2019). *Nutritional assessment* (7th ed.). McGraw-Hill Education.
- Nordestgaard, B. G. (2017). A test in context: Lipid profile, fasting versus nonfasting. *Journal of the American College of Cardiology*, 70(13), 1637–1646. <https://doi.org/10.1016/j.jacc.2017.08.006>
- Nurwanti, E., Hadi, H., Chang, J.S., Chao, J.C.J., Paramashanti, B.A., Gittelsohn, J., Bai, C.H., 2019. Rural–urban differences in dietary behavior and obesity: Results of the riskesdas study in 10–18-year-old Indonesian children and adolescents. *Nutrients* 11: 1–14. doi:10.3390/nu11112813
- Obaidullah MM, Chowdhury MR, et al. 2021. Analysis of the risk of cardiovascular diseases among people with diabetes according to triglyceride level. *J Adv Biotechnol Exp Ther.* 4(2):210–214.
- Panag KMD, Kaur N, Goyal G. 2014. Correlation of insulin resistance by various methods with fasting insulin in obese. *Int J Appl Basic Med Res.* 4(Suppl 1):S41–S45. <https://doi.org/10.4103/2229-516X.140733>
- Parikh, R., Mathai, A., Parikh, S., Sekhar, G. C., & Thomas, R. (2008). *Understanding and using sensitivity, specificity and predictive values.* *Indian Journal of Ophthalmology*, 56(1), 45–50.
- Paris T, George ES, Roberts SK, Tierney AC. 2017. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review. *Eur J Gastroenterol Hepatol.* 29(8):867–878. <https://doi.org/10.1097/MEG.0000000000000890>
- Perkeni. 2021. *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus tipe 2 di Indonesia.* Jakarta: PB Perkeni.
- Petrelli, F., Manara, M., Colombo, S., De Santi, G., Ghidini, M., Mariani, M., Iaculli, A., Rausa, E., Rampulla, V., Arru, M., Viti, M., Lonati, V., Ghidini, A., Luciani, A., & Facciorusso, A. (2022). Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and

- meta-analysis. *Neoplasia*, 30, 100809.
<https://doi.org/10.1016/j.neo.2022.100809>
- Petroff, D., Blank, V., Newsome, P.N., Shalimar, Voican, C.S., Thiele, M., et al., 2021. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. *Lancet Gastroenterol. Hepatol.* 6: 185–198. doi:10.1016/S2468-1253(20)30357-5
- Portincasa P. 2023. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. *Intern Emerg Med.* 18(4):993–1006. doi:10.1007/s11739-023-03203-0.
- Rachakonda V, Bataller R, Duarte-Rojo A. 2020. Recent advances in alcoholic hepatitis. *F1000Research*.9:F1000 Faculty Rev-97. doi:10.12688/f1000research.20394.1
- Ramírez-Vélez, R., Izquierdo, M., García-Hermoso, A., Correa-Rodríguez, M., 2024. Reference values and associated factors of controlled attenuation parameter and liver stiffness in adults: A cross-sectional study. *Nutr. Metab. Cardiovasc. Dis.* 34: 1879–1889. doi:10.1016/j.numecd.2024.04.004
- Reccia, I., Kumar, J., Akladios, C., Virdis, F., Pai, M., Habib, N., Spalding, D., 2017. Non-alcoholic fatty liver disease: A sign of systemic disease. *Metabolism.* 72: 94–108. doi:10.1016/j.metabol.2017.04.011
- Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia; 2018.
- Shaikh SS, Nafay S, Reshamwala SJ, Zaheer S, Sajid M. 2024. Assessment of liver fibrosis grading with non-invasive scoring systems among non-alcoholic fatty liver disease (NAFLD) patients. *Ann KEMU [Internet]*. 30(1):37–44. Available from: <https://annalskemu.org/journal/index.php/annals/article/view/5343>
- Shetty S, Rao A, Ireshanavar DS. 2020. Comparison of fasting and non-fasting lipid profile in healthy adult population. *Int J Clin Biochem Res.* 7(1):30–35.
- Siddiqui, M.S., Vuppalanchi, R., Van Natta, M.L., Hallinan, E., Kowdley, K. V., Abdelmalek, M., et al., 2019. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. *Clin. Gastroenterol. Hepatol.* 17: 156-163.e2. doi:10.1016/j.cgh.2018.04.043
- Sikaris, K. A. (2014). The clinical biochemistry of obesity. *The Clinical Biochemist Reviews*, 35(2), 109–121.
- Song SJ., 2024. Can we use old NAFLD data under the new MASLD definition? *J Hepatol.* 80(2):e54–e56.
- Song, K., Lee, H.W., Choi, H.S., Park, G., Lee, H.S., Kim, S.J., et al., 2022a. Comparison of the Modified TyG Indices and Other Parameters to Predict Non-Alcoholic Fatty Liver Disease in Youth. *Biology (Basel)*. 11: 1–13. doi:10.3390/biology11050685
- Song, K., Park, G., Lee, H.S., Lee, M., Lee, H.I., Ahn, J., et al. 2022b. Trends in prediabetes and non-alcoholic fatty liver disease associated with abdominal obesity among Korean children and adolescents: based on the Korea

- National Health and Nutrition Examination Survey between 2009 and 2018. *Biomedicines*. 10(3):584. <https://doi.org/10.3390/biomedicines10030584>
- Stefan, N., 2022. Screening for advanced liver fibrosis in overweight and obese patients with NAFLD. *Metab. Target Organ Damage* 2. doi:10.20517/mtod.2022.29
- Sulaiman, A.S., 2023. Perlemakan Hati Non-Alkoholik dan Risiko Fibrosis Hati pada Pasien Hepatitis B Kronik. *J. Penyakit Dalam Indones*. 10. doi:10.7454/jpdi.v10i3.1456
- Sun, Y., Ji, H., Sun, W., An, X., Lian, F., 2024. Triglyceride glucose (TyG) index: A
- Tanase, D.M., Gosav, E.M., Costea, C.F., Ciocoiu, M., Lacatusu, C.M., Maranduca, M.A., et al., 2020. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). *J. Diabetes Res*. 2020. doi:10.1155/2020/3920196
- Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2020). The complex link between NAFLD and type 2 diabetes mellitus—Mechanisms and treatments. *Nature Reviews Gastroenterology & Hepatology*, 17(11), 599–612. <https://doi.org/10.1038/s41575-020-0331-3>
- Tham, K.W., Abdul Ghani, R., Cua, S.C., Deerochanawong, C., Fojas, M., Hocking, S., et al., 2023. Obesity in South and Southeast Asia—A new consensus on care and management. *Obes. Rev*. 24. doi:10.1111/obr.13520
- Unger, G., Benozzi, S.F., Perruzza, F., Pennacchiotti, G.L., 2014. Triglycerides and glucose index: A useful indicator of insulin resistance. *Endocrinol. y Nutr.* (English Ed. 61: 533–540. doi:10.1016/j.endoen.2014.11.006
- United Nations Children’s Fund, 2022. Landscape Analysis of Overweight and Obesity in Indonesia. Unicef Indones.
- Wai, J.W., Fu, C., Wong, V.W.S., 2020. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. *J. Gastroenterol*. 55: 731–741. doi:10.1007/s00535-020-01686-8
- Wang, J., Yan, S., Cui, Y., Chen, F., Piao, M., Cui, W., 2022a. The Diagnostic and Prognostic Value of the Triglyceride-Glucose Index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis. *Nutrients* 14. doi:10.3390/nu14234969
- Wang, K., 2022b. Triglyceride-glucose index and the risk of non-alcoholic fatty liver disease: A meta-analysis. *Liver International*, 42(2), 261–270.
- Wong, V.W.S., Chan, W.K., Chitturi, S., Chawla, Y., Dan, Y.Y., Duseja, A., et al., 2018. Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment. *J. Gastroenterol. Hepatol*. 33: 70–85. doi:10.1111/jgh.13857
- World Health Organization. 2000. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; Available from: <https://iris.who.int/handle/10665/206936>
- Xie, W., Hong, Y., Chen, X., Wang, S., Zhang, F., Chi, X., 2024. Waist-to-hip ratio and nonalcoholic fatty liver disease: a clinical observational and Mendelian

- randomization analysis. *Front. Nutr.* 11: 1–11. doi:10.3389/fnut.2024.1426749
- Xue, M., 2022a. Association between triglyceride-glucose index and metabolic dysfunction-associated fatty liver disease. *Frontiers in Endocrinology*, 13, 914735. <https://doi.org/10.3389/fendo.2022.914735>
- Xue, Y., Xu, J., Li, M., Gao, Y., 2022b. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. *Front. Endocrinol. (Lausanne)*. 13: 1–12. doi:10.3389/fendo.2022.951689
- Yoneda, M., Fujii, H., Sumida, Y., Hyogo, H., Itoh, Y., Ono, M., et al., 2011. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. *Journal of Gastroenterology*, 46(11), 1300–1306. <https://doi.org/10.1007/s00535-011-0436-4>
- Younossi, Z. M., Paik, J. M., Stepanova, M., Ong, J., Alqahtani, S., & Henry, L. (2024). Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. *Journal of Hepatology*, 80(4), 694–701.
- Younossi, Z.M., Loomba, R., Rinella, M.E., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B.A., et al., 2018. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology* 68: 361–371. doi:10.1002/hep.29724
- Zeng, P., Cai, X., Yu, X., Gong, L., 2023a. Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population. *Sci. Rep.* 13: 1–8. doi:10.1038/s41598-023-47269-4
- Zeng, P., Cai, X., Yu, X., Huang, L., Chen, X., 2023b. HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population. *J. Int. Med. Res.* 51. doi:10.1177/03000605231204462.
- Zhang R, Guan Q, Zhang M, Ding Y, Tang Z, Wang H, Zhang W, Chen Y, Jiang R, Cui Y, Wang J. Association Between Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Cohort Study. *Diabetes Metab Syndr Obes.* 2022 Oct 19;15:3167-3179. doi: 10.2147/DMSO.S383907. PMID: 36268197; PMCID: PMC9578360.